Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy

Abstract Acute myeloid leukemia (AML), especially therapy-related (t-AML) or secondary AML (s-AML), presents complex therapeutic challenges. CPX-351, a liposomal formulation of cytarabine and daunorubicin, has demonstrated superior outcomes compared to standard 7 + 3 chemotherapy. However, optimal p...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Salvatore Perrone, Andrea Corbingi, Calogero Vetro, Fanny Erika Palumbo, Paola Minetto, Carola Riva, Laura Cicconi, Chiara Vernarecci, Roberto Massimo Lemoli, Alessandro Pulsoni, Fabio Guolo
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2026-02-01
Serija:	Annals of Hematology
Teme:	Acute myeloid leukemia CPX-351 Consolidation ARA-C Real-world evidence
Online dostop:	https://doi.org/10.1007/s00277-026-06784-w
Oznake:	Označite Brez oznak, prvi označite!